Economy and Reproducibility: Varying Virus Spike Conditions on a Planova 20N Virus-Removal Filter - - BioPharm International


Economy and Reproducibility: Varying Virus Spike Conditions on a Planova 20N Virus-Removal Filter

BioPharm International

Assuming normalized cost and similar V/m2 ratios, a bioprocess solution with two or three times higher concentration can result in a virus-filtration cost that is significantly lower on a robust filter. Simply put, the throughput on a g/m2 basis, with such a robust filter, could be much higher. This would serve to decrease filter per-unit cost, suite processing time, and filter integrity testing required. Additionally, if there is variation in the process at all (concentration, aggregation, etc.), robustness will also maintain reproducibility, which can serve to decrease costs associated with process exceptions and delays.


Planova 20N virus-removal filters demonstrate predictable and well-balanced performances that are unaffected by varying IgG concentration, virus purity, or spike percentage (i.e., constant protein filterability and consistent high LRV). This can serve to increase the economy and reproducibility of virus removal.


1. T.Hongo-Hirasaki, K.Yamaguchi, K.Yanagida, K.Okuyama, Removal of small viruses (parvovirus) from IgG solution by virus removal filter Planova20N. Journal of Membrane Science. Jul 2006;78(5):3–9.

2. K.Yamaguchi, E.Miyagawa, M.Dan, T.Miyazaki, H.Ikeda. Cellulose hollow fibers (BMMs) used in the filter membrane can trap human parvovirus (9). 15th ICEM Durban. South Africa. 2002;115–116.

3. T.Hongo-Hirasaki, K.Yamaguchi, K.Yanagida, K.Okuyama. Effects of varying virus-spike conditions in a virus-validation study on a Planova virus removal filter. IBC's 9th International Conference on well characterized biologicals and viral safety. VA, USA. 2005;Nov. 14–15.

Company info
Asahi Kasei Medical America
Long Island Branch, Planova Division
1600 Stewart Avenue, Suite 602
Westbury, NY 11590
Tel: 877.PLANOVA
Fax: 516.620.3135


blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here